Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, Steinborn J, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Mairinger FD. Borchert S, et al. Among authors: walter rfh. Sci Rep. 2020 Oct 29;10(1):18677. doi: 10.1038/s41598-020-75807-x. Sci Rep. 2020. PMID: 33122816 Free PMC article.
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J. Walter RF, et al. Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10. Br J Cancer. 2015. PMID: 25668009 Free PMC article.
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A. Mairinger FD, et al. Among authors: walter rfh. Oncotarget. 2018 Apr 27;9(32):22254-22268. doi: 10.18632/oncotarget.24962. eCollection 2018 Apr 27. Oncotarget. 2018. PMID: 29854276 Free PMC article.
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD. Walter RFH, et al. J Oncol. 2018 Jul 17;2018:1986982. doi: 10.1155/2018/1986982. eCollection 2018. J Oncol. 2018. PMID: 30112000 Free PMC article.
Setting out the frame conditions for feasible use of FFPE derived RNA.
Schmeller J, Wessolly M, Mairinger E, Borchert S, Hager T, Mairinger T, Schmid KW, Wohlschlaeger J, Walter RFH, Mairinger FD. Schmeller J, et al. Among authors: walter rfh. Pathol Res Pract. 2019 Feb;215(2):381-386. doi: 10.1016/j.prp.2018.12.027. Epub 2018 Dec 28. Pathol Res Pract. 2019. PMID: 30606660
39 results